TICKERNERD
Menu
ARWRARWRHealthcare · Biotechnology

ARWR Stock Forecast: Arrowhead Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$83
+0.11% on the day

The 13 Wall Street analysts covering Arrowhead Pharmaceuticals, Inc. hold a median 12-month price target of $106 — +27.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 57 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$11.7B
Ticker Nerd rank
57 / 100
Median analyst target
$106
Analysts covering
13
Revenue$75.3M+171.0% y/y
Operating income−$170.1M
Net income−$178.9M
Free cash flow−$181.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.2%
1M
−7.2%
YTD
+24.8%
1Y
+178.8%
From 52W high
−7.5%
From 52W low
+189.0%
$29
$90
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ARWR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Arrowhead Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
57 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
93
Momentum
90
Value
90
Accruals
74
Volatility
41
Revisions
39
Growth
38
Size
14
Issuance
12

Quality (93): The business earns solid, repeatable profits on what it owns.

Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ARWR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ARWR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100$120$140Oct 25Jan 26Apr 26Jul 26ARWRHigh $126Median $106Low $100

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
13 Buy0 Hold0 Sell
Low $100Median $106High $126

The green dot is the last close — the median target sits +27.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
8 Sept 2026CitigroupInitiatesBuy$108
1 Sept 2026HC Wainwright & Co.ReiteratesBuy$120
31 Aug 2026Chardan CapitalMaintainsBuy—
31 Aug 2026Chardan CapitalMaintainsBuy$115
31 Aug 2026RBC CapitalReiteratesOutperform—
31 Aug 2026RBC CapitalReiteratesOutperform$100
6 Aug 2026HC Wainwright & Co.MaintainsBuy$115 → $120
6 Aug 2026HC Wainwright & Co.MaintainsBuy—
30 July 2026B. Riley SecuritiesMaintainsBuy$101 → $123
30 July 2026B. Riley SecuritiesMaintainsBuy—
27 July 2026HC Wainwright & Co.MaintainsBuy—
27 July 2026HC Wainwright & Co.MaintainsBuy$100 → $115
23 July 2026Morgan StanleyMaintainsOverweight—
23 July 2026Morgan StanleyMaintainsOverweight$100 → $120
23 July 2026Piper SandlerReiteratesOverweight—
23 July 2026Piper SandlerReiteratesOverweight$110 → $126
22 July 2026Chardan CapitalMaintainsBuy$90 → $115
22 July 2026Chardan CapitalMaintainsBuy—
17 July 2026JP MorganMaintainsOverweight$88 → $95
17 July 2026JP MorganMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ARWR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ARWR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Arrowhead Pharmaceuticals, Inc. returned +178.8% against +17.5% for the S&P 500, dividends included.

ARWR vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Oct 25Jan 26Apr 26Jul 26ARWRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ARWR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
6
Fundamentals

Arrowhead Pharmaceuticals, Inc. (ARWR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
47.1×

Cheaper than 15% of US stocks

Price / sales
17.5×

Cheaper than 10% of US stocks

Price / book
25.1×

Cheaper than 4% of US stocks

EV / EBITDA
−57.2×

Cheaper than 95% of US stocks

Growth & margins
Revenue growth (YoY)
171.0%

Higher than 95% of US stocks

Earnings growth (YoY)
171.0%

Higher than 89% of US stocks

Gross margin
—
Operating margin
−226.0%

Higher than 10% of US stocks

Net margin
−47.8%

Higher than 11% of US stocks

Returns & dividend
Return on equity
−55.2%

Higher than 20% of US stocks

Return on assets
−8.1%

Higher than 28% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Arrowhead Pharmaceuticals, Inc. (ARWR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Arrowhead Pharmaceuticals, Inc. has a market value of $11.7B and an enterprise value of $11.5B.

  • Revenue in the twelve months to 30 June 2026: $669.5M. The latest quarter grew 171.0% year on year.

  • Net income over the same four quarters: −$272.1M, a −40.6% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$75.1M.

  • Shares outstanding: 141.1M.

  • Trailing P/E: 47.1×; forward P/E: −17.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Arrowhead Pharmaceuticals, Inc. employs 711 people — $942K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

ARWR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ARWRArrowhead Pharmaceuticals, Inc.$11.7B
57
AXSMAxsome Therapeutics, Inc.$11.4B
74
TECHBio-Techne Corp.$11.2B
94
CORTCorcept Therapeutics, Inc.$12.1B
79
HALOHalozyme Therapeutics, Inc.$12.2B
97
MDGLMadrigal Pharmaceuticals, Inc.$12.3B
69
BMRNBioMarin Pharmaceutical, Inc.$12.7B
64

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Arrowhead Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ARWR news & analysis

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Seeking Alpha · 10 Sept 2026neutral

Arrowhead Pharmaceuticals presented at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, and the transcript of that presentation has been published by Seeking Alpha.

Why it matters — ARWR watchers can review management's commentary from the conference presentation for insight into the company's ongoing business and pipeline updates.

Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million

The Motley Fool · 6 Sept 2026neutral

Arrowhead Pharmaceuticals reported that a director sold 11,600 shares for approximately $1 million. The transaction reduced the director's direct equity holdings by 9%.

Why it matters — Insider share sales can signal a director's changed outlook on the stock, so ARWR watchers may monitor such transactions for shifts in management confidence.

Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences

Business Wire · 3 Sept 2026neutral

Arrowhead Pharmaceuticals announced it will participate in several upcoming investor conferences in September 2026, including the Cantor Global Healthcare Conference, the Morgan Stanley 24th Annual Global Healthcare Conference, and the H.C. Wainwright conference, where the company is scheduled to give fireside chat presentations.

Why it matters — ARWR watchers would care because these scheduled fireside chat presentations give investors opportunities to hear directly from company management about its pipeline and strategy at major industry conferences.

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses SHASTA-3 and SHASTA-4 12-Month Results for Plozasiran in Severe Hypertriglyceridemia Transcript

Seeking Alpha · 31 Aug 2026neutral

Arrowhead Pharmaceuticals discussed the 12-month results of its SHASTA-3 and SHASTA-4 trials for plozasiran in patients with severe hypertriglyceridemia during a conference call, as detailed in a transcript. The discussion focused on the trial findings for the investigational therapy.

Why it matters — The 12-month data from these pivotal trials is a key clinical milestone for plozasiran, a lead candidate in Arrowhead's pipeline for severe hypertriglyceridemia.

Arrowhead's Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 Trials

MarketBeat · 31 Aug 2026positive

Arrowhead Pharmaceuticals presented 12-month results from its Phase 3 SHASTA-3 and SHASTA-4 trials evaluating plozasiran in adults with severe hypertriglyceridemia, reporting substantial reductions in triglycerides and acute pancreatitis events versus placebo. The data were presented at the European Society of Cardiology Congress in Munich and accepted for publication in a major medical journal.

Why it matters — The positive Phase 3 results for plozasiran signal meaningful clinical progress for one of Arrowhead's key pipeline candidates in treating severe hypertriglyceridemia.

FAQ

Frequently asked questions about ARWR stock

What is the ARWR stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Arrowhead Pharmaceuticals, Inc. have a median 12-month price target of $106, with estimates ranging from $100 to $126. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ARWR stock a buy right now?

Of the 13 analysts covering Arrowhead Pharmaceuticals, Inc., 13 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Arrowhead Pharmaceuticals, Inc. 57 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ARWR?

As at 12 Sept 2026, Arrowhead Pharmaceuticals, Inc. ranks 57 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (93 of 100).

Will ARWR stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +27.9% from the last close, and Ticker Nerd's factor model ranks Arrowhead Pharmaceuticals, Inc. 57 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ARWR stock forecast for 2030?

No analyst covering Arrowhead Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARWR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $100 to $126 over the next 12 months.

How has ARWR stock performed over the past year?

Arrowhead Pharmaceuticals, Inc. returned +178.8% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Arrowhead Pharmaceuticals, Inc. do?

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company that develops medicines for intractable diseases using RNA interference, a gene-silencing approach designed to reduce the production of disease-causing proteins.

What is the latest news on ARWR?

The most recent item we track (Seeking Alpha, 10 Sept 2026): "Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript". Arrowhead Pharmaceuticals presented at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, and the transcript of that presentation has been published by Seeking Alpha.

Company

About Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company that develops medicines for intractable diseases using RNA interference, a gene-silencing approach designed to reduce the production of disease-causing proteins. Arrowhead Pharmaceuticals focuses on therapeutic areas including cardiometabolic, liver, pulmonary, neuromuscular, complement-mediated, and central nervous system disorders. Its portfolio includes both commercial and clinical-stage programs built around its targeted RNAi platform, which is designed for tissue-specific delivery and precise gene suppression. The company works across product development, clinical research, and commercialization, with a pipeline that includes multiple investigational therapies aimed at genetically driven diseases. Arrowhead Pharmaceuticals serves the broader healthcare market by advancing treatments for complex conditions with limited options, positioning itself as a specialized player in RNA-based drug development.

CEO Dr. Christopher R. Anzalone Ph.D. · 711 employees · United States · https://arrowheadpharma.com